Skin & Hair

PTD-DBM

Also known as: CXXC5-Dishevelled disrupting peptide, Protein Transduction Domain-Dishevelled Binding Motif

Preclinical
Share:

Buy in shop

PTD-DBM from $115/kit

1 verified vendor, ≥99% purity, COAs included.

Compare prices

Key Facts: PTD-DBM

Category
Skin & Hair
FDA Status
Not FDA Approved
Clinical Status
Preclinical - animal (mouse) studies only, no human trials
Administration
Topical (applied to skin) in published research; usually co-applied with valproic acid
Typical Dose
Sold as 1 mg or 5 mg vials. A 5 mg vial in about 1 mL of water lands near the ~6 mg/mL used in the mouse study
Frequency
Once daily to the scalp in most community routines
Duration
Applied over several weeks in animal studies
Also Known As
CXXC5-Dishevelled disrupting peptide, Protein Transduction Domain-Dishevelled Binding Motif

Mechanism of Action

Hair follicles cycle into their growth (anagen) phase when Wnt/beta-catenin signaling switches on. CXXC5 is a negative feedback regulator of that pathway: it binds the intracellular protein Dishevelled (Dvl) and holds Wnt signaling down. PTD-DBM is a short Dvl-binding motif fused to a protein transduction domain (for cell entry) that competitively disrupts the CXXC5-Dvl interaction. With CXXC5 displaced, Dvl is free to activate Wnt/beta-catenin, which drives follicle stem-cell activation, anagen entry, and wound-induced hair neogenesis (new follicle formation in healing skin). It is typically studied together with valproic acid, a GSK-3beta inhibitor that pushes the same pathway from a different angle, so the two produce a synergistic effect greater than either alone. Be blunt: this mechanism is worked out in mice and cell models. The pathway is well characterized, but none of it has been validated in humans.

Research Summary

The core evidence comes from Lee SH and colleagues in the Choi laboratory at Yonsei University (South Korea), published in the Journal of Investigative Dermatology in 2017. In mice, topical PTD-DBM sped up the onset of anagen after shaving and promoted wound-induced hair neogenesis; a topical liquid of about 6 mg/mL PTD-DBM plus about 72 mg/mL valproic acid outperformed roughly 2% minoxidil in that model (the study reported these as solution concentrations: 2 mM, 500 mM, and 100 mM). The compound and its CXXC5-targeting mechanism are cited in more recent review articles on Wnt/beta-catenin hair therapies and short peptides for hair loss (2024-2025). What does not exist, as of 2026, is a single completed, peer-reviewed human efficacy trial. There is no FDA approval and no IND on record. Human dosing, safety, pharmacokinetics, and real-world efficacy are all unknown. The preclinical signal is genuinely interesting, but it is a long way from a proven treatment.

Trial Progress:Phase I
Pre
I
II
III
IV
FDA

Dosing Information

Animal Studies·Mouse-model preclinical research only, no human trials

Note: Animal study doses may not translate directly to humans.

Typical Dosing

Community experience

Common Dose

Sold as 1 mg or 5 mg vials. A 5 mg vial in about 1 mL of water lands near the ~6 mg/mL used in the mouse study

Range

Set by the user, no fixed dose

Frequency

Once daily to the scalp in most community routines

There is no proven human dose. What hair-loss communities actually do: reconstitute the mg vial with bacteriostatic water (a reconstitution calculator turns the vial's mg into a mg/mL strength), apply it to the scalp once a day, and pair it with topical valproic acid (VPA), the part that actually drives the hair response. Many also microneedle or dermaroll the scalp once or twice a week to help it absorb, and run it for one to three months. Some stack it with GHK-Cu or other hair peptides. All of this is anecdotal and unproven.

Research Dosing

Scientific studies

The mouse study used a topical liquid at roughly 6 mg/mL PTD-DBM plus roughly 72 mg/mL valproic acid. These are concentrations of the applied liquid, not a fixed per-dose amount, and there is no established human protocol.

Doses from Studies

~6 mg/mL PTD-DBM + ~72 mg/mL valproic acid, topical (study reported these as 2 mM and 500 mM)

Preclinical (mouse) study - Lee SH et al., J Invest Dermatol 2017 (Choi lab, Yonsei University)

Duration

Applied over several weeks in animal studies

Administration

Topical (applied to skin) in published research; usually co-applied with valproic acid

Timing & Administration

Best Time to Take

Not established (topical in animal studies)

No established human frequency

Food Recommendation

With or without food

Why This Timing?

No human timing data. In animal studies it was applied topically to the skin, generally alongside valproic acid.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • No human safety data exists
  • Local skin irritation is possible, largely from the valproic acid it is paired with
  • Theoretical cancer concern: sustained Wnt/beta-catenin activation is a known driver of some tumors, and long-term effects are unstudied
  • Unknown systemic absorption and long-term safety
  • Effects in humans are entirely unproven

References

Research This Peptide Further

Buy in shop

PTD-DBM from $115/kit

1 verified vendor, ≥99% purity, COAs included.

Compare prices

Frequently Asked Questions

What does PTD-DBM do?

PTD-DBM is a synthetic peptide studied for hair regrowth. It pairs a cell-penetrating protein transduction domain with a Dishevelled-binding motif, letting it slip into cells and block CXXC5, a natural brake on the Wnt/beta-catenin pathway that hair follicles use to enter their growth phase. In mouse studies, releasing that brake (usually alongside topical valproic acid) restarted hair growth and even formed new follicles in wounded skin. The honest catch: the entire efficacy record is preclinical and comes mostly from one lab. There are no completed human trials, no regulatory approval, and no proof it works on people. For research use only.

How does PTD-DBM work?

Hair follicles cycle into their growth (anagen) phase when Wnt/beta-catenin signaling switches on. CXXC5 is a negative feedback regulator of that pathway: it binds the intracellular protein Dishevelled (Dvl) and holds Wnt signaling down. PTD-DBM is a short Dvl-binding motif fused to a protein transduction domain (for cell entry) that competitively disrupts the CXXC5-Dvl interaction. With CXXC5 displaced, Dvl is free to activate Wnt/beta-catenin, which drives follicle stem-cell activation, anagen entry, and wound-induced hair neogenesis (new follicle formation in healing skin). It is typically studied together with valproic acid, a GSK-3beta inhibitor that pushes the same pathway from a different angle, so the two produce a synergistic effect greater than either alone. Be blunt: this mechanism is worked out in mice and cell models. The pathway is well characterized, but none of it has been validated in humans.

Is PTD-DBM FDA approved?

No, PTD-DBM is not currently FDA approved. Current status: Preclinical - animal (mouse) studies only, no human trials

What are the side effects of PTD-DBM?

Reported side effects include: No human safety data exists, Local skin irritation is possible, largely from the valproic acid it is paired with, Theoretical cancer concern: sustained Wnt/beta-catenin activation is a known driver of some tumors, and long-term effects are unstudied, Unknown systemic absorption and long-term safety, Effects in humans are entirely unproven. Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of PTD-DBM?

Community-reported common dose: Sold as 1 mg or 5 mg vials. A 5 mg vial in about 1 mL of water lands near the ~6 mg/mL used in the mouse study (Once daily to the scalp in most community routines). Range: Set by the user, no fixed dose. Administration: Topical (applied to skin) in published research; usually co-applied with valproic acid. Community-reported, anecdotal use. Not proven, not medical advice. For research use only.

Related Peptides

Peptides commonly compared with PTD-DBM or used in similar applications.

GHK-Cu

Clinical Trials

GHK-Cu is the copper(II) complex of GHK, a naturally occurring human tripeptide (glycyl-L-histidyl-L-lysine) found in blood plasma, saliva and urine, whose levels decline with age. It is researched and widely used in cosmetic skincare for skin regeneration, wound healing, collagen support and anti-aging. It is not an FDA-approved drug; it appears in over-the-counter cosmetics and as a research or compounded peptide, with most human evidence coming from small topical-skincare studies.

Skin & Hair

Snap-8

Research

SNAP-8 (Acetyl Octapeptide-3) is a synthetic eight-amino-acid topical cosmetic peptide, an extended cousin of Argireline that adds two residues to the same SNAP-25 mimic sequence. It is marketed as a needle-free way to soften expression lines, especially on the forehead and around the eyes. It is a cosmetic ingredient, not an approved drug, and the human evidence behind it is thin and mostly comes from the manufacturer.

Skin & Hair

Argireline

Research

Argireline is the trade name for acetyl hexapeptide-8 (sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, also called acetyl hexapeptide-3), a synthetic peptide sold in anti-aging creams as a topical, needle-free alternative to Botox. It is designed to relax the muscle contractions behind expression lines. It is a cosmetic ingredient, not an FDA-approved drug, and the human efficacy data are genuinely mixed rather than settled.

Skin & Hair

Matrixyl

Research

Matrixyl is the trade name (Sederma) for palmitoyl pentapeptide-4, also written Pal-KTTKS, a collagen-fragment peptide attached to a fatty acid so it can cross skin. Unlike Botox-mimic peptides, it does not touch muscle: it signals skin cells to rebuild collagen, so it is aimed at fine lines, firmness and skin texture rather than expression wrinkles. It is a cosmetic ingredient with one of the better-documented topical studies in the peptide space, though far short of drug-grade proof.

Skin & Hair

Matrixyl 3000

Research

Matrixyl 3000 is Sederma's follow-up to the original Matrixyl, a fixed pair of two fatty-acid-tagged peptides: palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapeptide-7 (Pal-GQPR). The idea is a one-two punch: one peptide tells skin to rebuild collagen, the other calms the low-grade inflammation that wears collagen down. It is a cosmetic ingredient aimed at firmness, fine lines and aging skin, with supportive but mostly company-generated evidence.

Skin & Hair

Copper Peptide AHK-Cu

Research

AHK-Cu is a synthetic copper-bound tripeptide, alanine-histidine-lysine complexed with a copper ion, engineered mainly for hair and scalp products. It is the lesser-known sibling of the naturally occurring GHK-Cu copper peptide, designed in the lab specifically to push hair follicles to keep growing. It is a cosmetic and research ingredient, not an approved hair-loss drug, and its evidence is essentially limited to one notable lab study.

Skin & Hair

Want updates on PTD-DBM research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.